# Skeptic's Assessment: The Amyloid Cascade Hypothesis
## Lead: Falsifiability Failure
The amyloid cascade hypothesis (ACH) has not been *falsified* — it has been *disconfirmed* by Phase 3 trials. Multiple large trials of amyloid-lowering agents (bapineuzumab, solanezumab, semagacestat) failed to meet primary cognitive endpoints despite successfully reducing amyloid burden (PMID: **22665828**, **24906972**). A hypothesis whose core prediction — *reducing amyloid improves cognition* — has repeatedly failed is no longer "best explanation." It's the leading survivor of falsification, not its victor.
---
## Weaknesses in the Evidence
### 1. Correlation ≠ Causation
The foundational evidence is epidemiological and neuropathological: elevated Aβ correlates with AD. This is the same logical trap that made cholesterol → heart disease the dominant model for decades until the data required revision. Early-onset familial AD shows Aβ buildup precedes symptoms, but this is a minority (~5%) of cases. For *sporadic* late-onset AD (95% of cases), Aβ accumulation may be a downstream consequence, not upstream cause (PMID: **29128392**).
### 2. Preclinical Accumulation with Normal Cognition
Aβ plaques are detected by PET imaging in **20-40% of cognitively normal individuals over 65** (PMID: **18772504**). If Aβ is the cascade trigger, why do these individuals not progress to AD? This is not a minor confound — it's a falsification test the hypothesis has failed to pass.
### 3. Temporal Paradox
If amyloid accumulation initiates a cascade leading to tau pathology, neurodegeneration, and cognitive decline over decades, why does removing amyloid in *mild-to-moderate* AD patients (the majority of trials) fail to halt progression? Either the cascade is already irreversible by symptomatic stages, or Aβ isn't the trigger.
---
## Counter-Evidence & Alternative Explanations
### The Vascular Hypothesis Has Stronger Explanatory Power for Sporadic AD
- Cerebrovascular pathology (microinfarcts, white matter lesions, blood-brain barrier breakdown) shows stronger correlation with cognitive impairment than amyloid in some cohorts (PMID: **30585786**, **32271324**).
- APOE4's effects on lipid transport and vascular function may explain its AD risk more parsimoniously than Aβ acceleration.
- The SVD (small vessel disease) - AD overlap is >60% in neuropathological series.
### Neuroinflammation as Primary Driver
- TREM2 variants (reducing microglial Aβ clearance) implicate immune dysfunction *early* in pathogenesis (PMID: **24670649**).
- Human iPSC models show microglial-mediated Aβ phagocytosis as a key disease modifier.
- The "Aβ first, inflammation second" model hasn't been definitively established in humans.
### Tau Spread Model Competes
- Tau pathology correlates more strongly with cognitive decline than amyloid (PMID: **26646930**).
- Synaptic loss precedes amyloid deposition in some longitudinal studies.
- The hypothesis may have the causation reversed: Aβ accumulation may be a result of synaptic failure and metabolic stress.
---
## Revised Confidence Score
| Original confidence in ACH | Evidence quality | Revised confidence |
|---|---|---|
| ~0.85 for familial AD | Strong for early-onset | ~0.75 |
| ~0.70 for sporadic AD | Multiple trial failures | ~0.35–0.40 |
**ACH remains a plausible contributor to AD pathogenesis, particularly in early-onset familial forms. It is *not* the best explanation for sporadic late-onset AD, where vascular, inflammatory, and metabolic factors collectively appear more explanatory.**
---
## What Would Falsify Alternative Hypotheses?
- Blocking tau seeding without affecting Aβ must improve outcomes in sporadic AD.
- Demonstrating that vascular normalization (e.g., antihypertensives) halts Aβ accumulation in humans would invert causality.
- Genetic evidence that *only* Aβ pathway genes (not vascular/immune genes) modify sporadic AD risk.
---
## Conclusion
The amyloid cascade hypothesis has the historical advantage of being **first, most funded, and most tested**. That is not the same as being **best-supported**. Science progresses not by defending leading hypotheses but by subjecting them to the trials they've already failed. The field's continued investment in amyloid-centric therapies despite repeated disconfirmation is itself a candidate for scrutiny — a classic sunk-cost trap.
The honest answer: **ACH explains some of AD, but much of the disease remains unexplained by this framework.**